Cambridge-to-Cambridge collaboration could be worth $35 million to Abzena

22 December 2016

US biotech start-up Trieza Therapeutics has acquired exclusive worldwide rights to an undisclosed antibody sequence for exploitation in conjunction with its viral vector technology to develop novel therapies in oncology.

The deal is with Abzena (AIM: ABZA), which like Trieza is based in Cambridge – albeit the UK city rather than the Massachusetts version - and could be worth up to $35 million in development and commercial milestone payments as well as royalties on the sale of licensed products containing the Abzena sequence.

News of the deal sent Abzena’s share price up by more than 5% on Thursday to £35.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK